Respected pharmaceutical entity, Regeneron Pharmaceuticals Inc., partially conceded to infringing on a patent held by a California-based company in their efforts to create and test COVID-19 vaccines and treatments. This admission, however, comes with a firm stance from Regeneron that their potential liability would not encompass activities falling under a federal ‘safe harbor’. This term commonly refers to certain legal protections for entities when their actions may technically infrince on patent rights.
As challenging as it seems for such a prominent company, recognizing, albeit partially, such infringements in the field of pharmaceuticals not only affirms the existence of robust IP (intellectual property) controls, but also underlines the complexities of vaccine development in extraordinary times such as a global pandemic.
For the original legal reporting and detailed insights on this matter, legal professionals can delve deeper into the story at Law360.